
|Videos|January 22, 2019
Time Points in the Assessment of MRD
Advertisement
" width="560">Transcript:Mark R. Litzow, MD: Anthony, when do you think we should be measuring MRD?
Anthony S. Stein, MD: I think it also depends which regimen you
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































